This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Top 5 Must-Follow Earnings for Monday

Stocks in this article: VVUS STX APC FST MAS

NEW YORK ( TheStreet) -- Another week into earnings season and Wall Street is still moving at full speed. Here is what to watch on Monday.

Vivus (VVUS)

Who They Are: Vivus is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. Vivus trades an average of 14.1 million shares per day with a marketcap of $2.2 billion.

VVUS Chart VVUS data by YCharts

Vivus is forecast to record shallow second-quarter earnings after the market closes July 30. The consensus estimate is currently a loss of 23 cents a share, another drop of three cents from a loss of 20 cents during the equivalent quarter last year.

Analyst opinion is mixed with this company. Most of the analysts surveyed don't believe a buy or a sell is currently warranted. Right now, Vivus has five buy recommendations out of 11 analysts covering the company, six holds, and no analysts recommend selling.

Four out of 11 analysts now rate Vivus a strong buy down from five analysts a month ago. Compared to three months ago, fewer analysts are rating this company as a strong buy. The stock has appreciated 180% in the last year, and the average analyst target price for Vivus is $38.29.

It's not a typo, Vivus really is up 180% and it was on my radar a lot.

The last date Vivus released earnings was May 7, and the closing price before earnings was $23.58. Based on Tuesday's closing price of $23, shares are down 2.5%.

The bottom line has falling earnings year-over-year with a loss of $46.14 million last fiscal year compared to an even bigger loss of $66.07 million in the previous year.

With 15% short interest, investors better know what they are doing before picking this one up -- 15% is the sweet spot for short interest as a bearish indicator. I like what they do as a company, but I would avoid the stock as an investment at this level. The earnings release may not have much of an impact either way because of the binary reaction pharmaceuticals have to trial results.

1 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs